Sci Simple

New Science Research Articles Everyday

# Health Sciences # Hematology

Everything You Need to Know about Beta Thalassemia

Learn about beta thalassemia, its types, symptoms, and treatments.

Oluwatoyin Aduke Babalola, Foluke Atinuke Fasola, Biobele Jotham Brown, Jing Zhang, Yonglan Zheng, Abayomi Odetunde, Adeyinka Gladys Falusi, Olufunmilayo Olopade

― 5 min read


Beta Thalassemia Beta Thalassemia Uncovered and its impacts. Dive into the world of beta thalassemia
Table of Contents

Beta thalassemia is a blood disorder that affects how the body makes hemoglobin, the protein that carries oxygen in red blood cells. This disorder is often inherited, meaning it can be passed down from parents to children. In beta thalassemia, there is a problem with the beta-globin gene, which can lead to a lack of or low levels of beta-globin production. Because of this, the body produces less adult hemoglobin (HbA), which can lead to anemia—a condition where you don’t have enough red blood cells to carry oxygen throughout the body.

Types of Beta Thalassemia

There are three main types of beta thalassemia:

  1. Beta Thalassemia Minor: This is the mildest form and often goes undetected. Individuals may not show any symptoms or have only a mild reduction in hemoglobin levels.

  2. Beta Thalassemia Intermedia: This form is more severe than minor but not as severe as major. Individuals may experience anemia and require occasional Blood Transfusions.

  3. Beta Thalassemia Major: This is the most severe form, often diagnosed in early childhood. Patients with this condition usually require regular blood transfusions to manage their anemia.

Where is Beta Thalassemia Common?

Beta thalassemia can be found all over the world. However, it is most common in certain regions. Areas with a high prevalence include the Mediterranean, Middle East, and Southeast Asia. A bit surprisingly, places like North America and Northern Europe see lower rates. Due to migration and intermixing of populations, even areas that did not previously have high cases of the disorder are now seeing more instances.

For instance, Cyprus and Sardinia boast some of the highest rates of carriers of beta thalassemia. In Nigeria, studies say that rates of beta thalassemia minor can be around 25%, though some reports suggest that the real number is much lower.

The Genetics Behind Beta Thalassemia

The beta-globin gene, which is the culprit behind this disorder, is found on chromosome 11. This gene is pretty complex, made up of three exons (the parts that code for protein) and three introns (the non-coding sections). Variations in this gene, known as mutations, can lead to different forms of beta thalassemia. Scientists have identified around 300 mutations that can cause this condition.

When a person has mutations affecting their beta-globin gene, their body might produce less hemoglobin or not produce it at all. The severity of symptoms can vary greatly depending on the specific mutation and whether the person inherits one or two mutated genes.

Understanding Symptoms

People with beta thalassemia, especially in its major form, may face various symptoms, including:

  • Fatigue
  • Weakness
  • Paleness
  • Shortness of breath
  • Delayed growth in children

In severe cases, individuals may experience bone deformities and swelling in the abdomen due to an enlarged spleen.

Testing for Beta Thalassemia

If someone suspects they have beta thalassemia or if it runs in their family, doctors usually perform blood tests. These tests can measure hemoglobin levels and the proportion of different types of hemoglobin. If necessary, more advanced tests like DNA testing can identify specific mutations in the beta-globin gene.

How is Beta Thalassemia Treated?

Treatment for beta thalassemia largely depends on its severity. For mild cases, no treatment is often needed. For more severe forms, treatments may include:

  • Regular Blood Transfusions: These help manage anemia by providing healthy red blood cells.
  • Iron Chelation Therapy: Since blood transfusions can lead to excess iron in the body, this therapy helps remove that excess iron to prevent complications.
  • Folic Acid Supplements: Folic acid can help the body produce more red blood cells.
  • Bone Marrow Transplant: This is a potential cure for some young patients with severe beta thalassemia, though it comes with risks.

Living with Beta Thalassemia

Living with beta thalassemia can be challenging, but many people manage to live full lives with appropriate care. Regular check-ups, monitoring blood health, and sticking to treatment plans are vital for keeping symptoms under control.

Support groups and educational resources can also provide helpful information and community support for those affected and their families.

The Link with Sickle Cell Disease

Interestingly, beta thalassemia is linked to another blood disorder known as sickle cell disease (SCD). Both conditions arise from mutations in the same gene. Someone can inherit both conditions, leading to a mix of symptoms from each disorder. The severity of symptoms may vary depending on the specific mutations involved.

Conclusion

Beta thalassemia is a complex blood disorder resulting from genetic mutations affecting hemoglobin production. While it can lead to significant health challenges, awareness, early diagnosis, and modern medical treatments can help many manage the condition effectively. The study of this disorder not only helps those affected but also provides insights into the fascinating world of genetics and human health.

So next time you hear someone murmur about hemoglobin, now you can nod knowingly—after all, that's where the drama of beta thalassemia plays out!

Final Thoughts

Beta thalassemia may not be a household name, but it is part of the intricate story of how our genes shape our health. It serves as a reminder of the importance of genetic research and understanding inherited conditions. And while dealing with diseases like beta thalassemia may not be a walk in the park, with the right knowledge and support, individuals can navigate their health with confidence and resilience.

Original Source

Title: The genetic architecture of the β-globin chain in individuals with and without sickle cell disease in Nigeria: A case for beta thalassemia?

Abstract: BackgroundReports on beta thalassemia in the Nigerian population are conflicting, and the prevalence and role of beta thalassemia in Nigerian sickle cell disease (SCD) patients remain unclear. There is a need to set the records straight to ascertain the prevalence and effect of beta thalassemia in these patients. Methods123 SCD patients and 117 age- and sex-matched controls were recruited. For the cases, the age range was 3 - 69 years, median(IQR) = 16(9 - 29). A separate cohort of 26 SCD patients were studied along. Full blood count was calculated, and the hemoglobin fractions were estimated by High Performance Liquid Chromatography. The 1.6kb beta-globin gene region was amplified from germline DNA and Sanger sequencing was performed. Single nucleotide polymorphisms (SNPs) were detected and annotated, and haplotypes were constructed. ResultsContrary to recent reports, the prevalence of beta thalassemia in this population is A) was found on the minor ancestral haplotype, atypical of Africa. Two rare variants (rs537944366T>C and rs33915217C>A) are reported for the first time in the Yoruba population. ConclusionThere is a need for a re-assessment of the diagnosis of beta thalassemia in this and other African populations for the proper management of SCD and other anemia-related cases.

Authors: Oluwatoyin Aduke Babalola, Foluke Atinuke Fasola, Biobele Jotham Brown, Jing Zhang, Yonglan Zheng, Abayomi Odetunde, Adeyinka Gladys Falusi, Olufunmilayo Olopade

Last Update: 2024-12-24 00:00:00

Language: English

Source URL: https://www.medrxiv.org/content/10.1101/2024.12.20.24319473

Source PDF: https://www.medrxiv.org/content/10.1101/2024.12.20.24319473.full.pdf

Licence: https://creativecommons.org/licenses/by-nc/4.0/

Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.

Thank you to medrxiv for use of its open access interoperability.

More from authors

Similar Articles